Exploration of the Clonal Evolution and Construction of the Tumor Clonal Evolution Rate As a Prognostic Indicator in Metastatic Breast Cancer

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2025 Feb 26

PMID 40001125

Authors

Dan Lv

Bo Lan

Qihan Guo

Zongbi Yi

Haili Qian

Yanfang Guan

Xuenan Peng

Ting Chen

Fei Ma

Affiliations

Soon will be listed here.

Abstract

Background: Tumor heterogeneity and clonal evolution are related to the treatment resistance and disease progression in metastatic breast cancer (MBC). However, the process of clonal evolution and their relationship to prognosis remain unclear. This study aimed to elucidate the evolution of MBC through circulating tumor DNA (ctDNA) analysis and to develop a novel indicator for predicting treatment efficacy and prognosis.

Methods: This multicenter retrospective study enrolled MBC patients who underwent next-generation sequencing between April 2016 and October 2022. The clonal evolution of tumors was inferred using PyClone and CITUP software.

Results: The study included 406 MBC patients. A cohort of 139 patients from the National Cancer Center served as the training cohort, while 267 patients from other centers comprised the validation cohort. In the training cohort, clonal analysis revealed that most MBCs exhibited branched clonal evolution, while a minority showed linear evolution. The branched evolution pattern was associated with slower disease progression (HR, 0.53; 95% CI, 0.32-0.87; P = 0.012). We introduced tumor clonal evolution rate (TER) as a novel concept to reflect the speed of clonal evolution. Survival analysis demonstrated that compared to the TER-high group, patients in the TER-low group had better progression-free survival (PFS) (HR, 0.62; 95% CI, 0.40-0.96; P = 0.033) and overall survival (OS) (HR, 0.45; 95% CI, 0.24-0.85; P = 0.013). Similarly, in the validation cohort, although the median OS was not reached, patients in the TER-low group had better prognosis compared to those in the TER-high group (HR, 0.41; 95% CI, 0.21-0.83; P < 0.001).

Conclusions: Patients with branched evolution have better treatment efficacy than those with linear evolution. The TER shows potential as a biomarker for treatment efficacy and prognosis, providing new evidence that ctDNA is a valuable molecular indicator for predicting treatment outcomes in metastatic breast cancer.

References

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Ai X, Cui J, Zhang J, Chen R, Lin W, Xie C . Clonal Architecture of Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clin Cancer Res. 2020; 27(3):704-712. DOI: 10.1158/1078-0432.CCR-20-3063. View

Yi Z, Yu P, Zhang S, Wang W, Han Y, Ouyang Q . Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2020; 148(3):692-701. DOI: 10.1002/ijc.33227. View

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View

Pellini B, Chaudhuri A . Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. J Clin Oncol. 2022; 40(6):567-575. PMC: 8853615. DOI: 10.1200/JCO.21.01929. View

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang M . Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015; 7(8):1034-47. PMC: 4551342. DOI: 10.15252/emmm.201404913. View

Valastyan S, Weinberg R . Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-92. PMC: 3261217. DOI: 10.1016/j.cell.2011.09.024. View

Rong G, Yi Z, Ma F, Guan Y, Xu Y, Li L . DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. Ann Transl Med. 2021; 9(3):220. PMC: 7940884. DOI: 10.21037/atm-20-2137. View

Van Poznak C, Somerfield M, Bast R, Cristofanilli M, Goetz M, Gonzalez-Angulo A . Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015; 33(24):2695-704. PMC: 5478102. DOI: 10.1200/JCO.2015.61.1459. View

10.

Yi Z, Ma F, Rong G, Liu B, Guan Y, Li J . The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021; 6(1):251. PMC: 8260637. DOI: 10.1038/s41392-021-00662-9. View

11.

Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S . Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2019; 146(5):1359-1368. DOI: 10.1002/ijc.32536. View

12.

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

13.

Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C . Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2013; 343(6167):189-193. PMC: 3998672. DOI: 10.1126/science.1239947. View

14.

Tellez-Gabriel M, Knutsen E, Perander M . Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. Int J Mol Sci. 2020; 21(24). PMC: 7763984. DOI: 10.3390/ijms21249457. View

15.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

16.

Wu H, Wang Z, Zhao Q, Chen D, He M, Yang L . Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2020; 7(22):640. PMC: 6944566. DOI: 10.21037/atm.2019.10.116. View

17.

Zhai W, Kiat-Hon Lim T, Zhang T, Phang S, Tiang Z, Guan P . The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun. 2017; 8:4565. PMC: 5333358. DOI: 10.1038/ncomms14565. View

18.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

19.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View